Chase Investment Counsel Corp Gilead Sciences, Inc. Transaction History
Chase Investment Counsel Corp
- $313 Million
- Q2 2025
A detailed history of Chase Investment Counsel Corp transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Chase Investment Counsel Corp holds 10,294 shares of GILD stock, worth $1.23 Million. This represents 0.36% of its overall portfolio holdings.
Number of Shares
10,294
Previous 7,945
29.57%
Holding current value
$1.23 Million
Previous $890,000
28.2%
% of portfolio
0.36%
Previous 0.33%
Shares
6 transactions
Others Institutions Holding GILD
# of Institutions
2,347Shares Held
1.03BCall Options Held
12.1MPut Options Held
9.13M-
Black Rock Inc. New York, NY121MShares$14.5 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA119MShares$14.3 Billion0.22% of portfolio
-
State Street Corp Boston, MA59.2MShares$7.09 Billion0.25% of portfolio
-
Capital World Investors Los Angeles, CA46.3MShares$5.55 Billion0.78% of portfolio
-
Wellington Management Group LLP Boston, MA37.5MShares$4.5 Billion0.79% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $150B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...